Yazar "Mutlu, Hasan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Glossodynia induced by panitumumab in metastatic colorectal cancer: report of two cases
    (Turgut Özal Tıp Merkezi Dergisi, 2016) Eryılmaz, Melek Karakurt; Mutlu, Hasan; Musrı, Fatma Yalçın; Tazegül, Gökhan; Salim, Derya Kıvrak; Çoşkun, Hasan Şenol
    Abstract Objective: To examine hip development in a patient who underwent Dega osteotomy due to developmental dysplasia of the hip (DDH) by means of radiography. Materials and Methods: Dega osteotomy was performed on 43 hips (7 were bilateral) of 36 patients with DDH. In preoperative and final follow-up; the acetabular index (AI), acetabular depth ratio (ADR) and Wiberg's center-edge angle (CEA) were measured in anteroposterior pelvic radiographs. Hips were classified in accordance with Tönnis classification system. Radiological findings were evaluated in accordance with Severin classification system. Avascular necrosis (AVN) of the hips were evaluated according to Kalamchi-MacEwen classification system. Results: The mean age was 87 months (48-130 months), mean follow-up period was 30.5 months (15-62 months). The mean preoperative and final follow-up values of AI were 43° (28°to 60°) and 19° (6° to 34°), respectively. The mean preoperative and final follow-up values of ADR were detected as 14 (8 to 24) and 26 (18 to 42), respectively.The mean CEA was found as 38° (18° to 61°) at the final follow-up. Of the hips, 37 were Tönnis type 4 and 6 were Type 3. Totally 10 hips had AVN; of those, 6 were Type 1, 2 were Type 2 and 2 were Type 3 hips. According to Severin classification, 11 hips were Type 1a, 3 were Type 1b, 22 were Type 2a, 5 were Type 2b and 2 were Type 3. Conclusion: In patients who underwent Dega osteotomy, hip development can be detected radiographically with satisfactory levels. Keywords:.Hip; Dysplasia; Osteotomy.
  • Küçük Resim
    Öğe
    Glossodynia induced by panitumumab in metastatic colorectal cancer: report of two cases
    (Turgut Özal Tıp Merkezi Dergisi, 2016) Eryılmaz, Melek Karakurt; Mutlu, Hasan; Musrı, Fatma Yalçın; Tazeğül, Gökhan; Salim, Derya Kıvrak
    Abstract Colorectal cancer (CRC) is the third most common cancer, and is the third most common cause of death due to cancer in both women and men. Approximately 20 percent of patients with newly diagnosed colon cancer have distant metastatic disease at the time of diagnosis. Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and it is commonly used to treat metastatic colorectal cancer (mCRC). Combinations of panitumumab plus an irinotecan or oxaliplatin-based regimen are reasonable both first-line and second-line options for mCRC with RAS wild type tumors. However, it has been associated with various side effects such as papulopustular acneiform rash, hypomagnesemia, and diarrhea. No previous reports on patients who developed tongue pain without stomatitis while treatment with panitumumab exists in the literature. Here we report two cases that developed tongue pain while on panitumumab for mCRC. Keywords: Panitumumab; Tongue Pain; Metastatic Colorectal Cancer.
  • Küçük Resim
    Öğe
    Glossodynia induced by panitumumab in metastatic colorectal cancer: report of two cases
    (Turgut Özal Tıp Merkezi Dergisi, 2016) Eryılmaz, Melek Karakurt; Mutlu, Hasan; Musrı, Fatma Yalçın; Tazegül, Gökhan; Salim, Derya Kıvrak; Çoşkun, Hasan Şenol
    Abstract Colorectal cancer (CRC) is the third most common cancer, and is the third most common cause of death due to cancer in both women and men. Approximately 20 percent of patients with newly diagnosed colon cancer have distant metastatic disease at the time of diagnosis. Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and it is commonly used to treat metastatic colorectal cancer (mCRC). Combinations of panitumumab plus an irinotecan or oxaliplatin-based regimen are reasonable both first-line and second-line options for mCRC with RAS wild type tumors. However, it has been associated with various side effects such as papulopustular acneiform rash, hypomagnesemia, and diarrhea. No previous reports on patients who developed tongue pain without stomatitis while treatment with panitumumab exists in the literature. Here we report two cases that developed tongue pain while on panitumumab for mCRC. Keywords: Panitumumab; Tongue Pain; Metastatic Colorectal Cancer.